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Background: The incidence of uveitis associated with juvenile idiopathic arthritis (JIA) varies around the world. Our
aim was to investigate the incidence and predictors of uveitis in a Nordic population-based cohort.
Methods: Consecutive JIA cases from defined geographical areas in Denmark, Finland, Sweden and Norway with
disease onset between January 1997 to June 2000 were followed for median 98 months in this prospective
longitudinal cohort study. Potential clinical and immunological predictors of uveitis were identified with logistic
regression analysis.
Results: Uveitis occurred in 89 (20.5%) of the 435 children with regular ophtalmologic follow-up among the 500
included. Chronic asymptomatic uveitis developed in 80 and acute symptomatic uveitis in 9 children. Uveitis
developed at a median interval of 0.8 (range − 4.7 to 9.4) years after onset of arthritis. Predictors of uveitis were
age < 7 years at JIA onset (Odds ratio (OR) 2.1, 95% confidence interval (CI) 1.3 to 3.5), presence of antihistone
antibodies (AHA) > 15 U/ml (OR 4.8 (1.8 to 13.4)) and antinuclear antibodies (ANA) (OR 2.4 (1.5 to 4.0)). Mean combined
IgM/IgG AHA was significantly higher in the uveitis group (19.2 U/ml) than in the non-uveitis group (10.2 U/ml)
(p = 0.002). Young age at JIA onset predicted uveitis in girls (p < 0.001), but not in boys (p = 0.390).
Conclusion: Early-onset arthritis and presence of AHA in girls, as well as presence of ANA in both genders, were
significant predictors of chronic uveitis. The high incidence of uveitis in this long-term Nordic JIA cohort may have
severe implications in a lifelong perspective.
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Uveitis is the most common extra-articular manifest-
ation of juvenile idiopathic arthritis (JIA). This sight-
threatening condition contributes significantly to the
disease burden of JIA [1, 2]. Chronic insidious uveitis in
JIA is often asymptomatic, and it is a major challenge to
diagnose the condition as early as possible for prompt
and adequate treatment [3, 4]. The diagnosis may be ob-
vious in cases with acute uveitis [5], but the challenge* Correspondence: ellen.nordal@icloud.com
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treatment to minimize long-term complications in all
forms of JIA-associated uveitis. The reported preva-
lence of uveitis in JIA varies highly, and ethnic and geo-
graphic differences seem to exist. Recent publications
show a prevalence of 8–25% in most Caucasian po-
pulations [6, 7], while some studies from other conti-
nents show lower percentage of uveitis, 1 to 7% [8, 9].
Young age at onset of arthritis and presence of ANA
were predictors of uveitis in most studies [3, 10–12]. In
some larger cohort studies and registries, oligoarticular
onset category and female gender were also statistically
significant predictors of uveitis, but with less clinical
impact [3, 13].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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these basic DNA-binding proteins are found in highly
organized nucleosomal particles [14]. Antihistone anti-
bodies (AHA) are among the ANA subtypes identified
in subsets of children with JIA, while other subtypes as-
sociated with connective tissue diseases such as anti-
DNA, anti-RNP, anti-SSA and anti-SSB antibodies are
rarely found [15, 16]. AHA were reported to be associ-
ated with early-onset JIA, oligoarthritis and uveitis [17].
We showed previously that AHA is a significant pre-
dictor of chronic uveitis in a Norwegian JIA cohort [11].
Whether this association is merely an epiphenomenon is
not yet known, although new interest for histones in
autoimmune diseases has emerged through recent epi-
genetic findings [18, 19].
A longitudinal cohort study of JIA in a population-
based setting in the Nordic countries started in 1997
and is still ongoing [20, 21]. The ophthalmologic data of
a follow-up 8 years after disease onset of this Nordic JIA
cohort were analyzed in the present study. The main ob-
jective was to describe the incidence and the predictors
of uveitis in JIA during the first decade after disease on-
set. We also wanted to extend the previous Norwegian
pilot study to the Nordic JIA cohort regarding the pres-




In this longitudinal study, children with long-term oph-
thalmologic follow-up were selected from a prospective
multicentre Nordic JIA cohort. The original multicentre
cohort consisted of consecutive children with newly di-
agnosed JIA and disease onset between January 1, 1997
to June 30, 2000 from defined geographical areas of
Denmark, Finland, Norway and Sweden aiming for the
cohort to be population-based [20]. Clinical information
including family history, assessment of disease activity,
self-reported questionnaires and information from oph-
thalmology visits was registered per protocol at baseline
and at 1 to 3 year intervals. Detailed description of the
methods of patient accrual and data collection has been
published previously [21].
At the final study visit, at least 7.0 years (median
98 months, range 84–147 months) after disease onset,
extended data including information from the most re-
cent ophthalmologic visit was collected. The interval of
ophthalmologic visits was every 2–3 months the first
2 years, then longer intervals according to time after dis-
ease onset and JIA category. The intervals were in line
with the guidelines for uveitis screening at each center,
based on international uveitis screening guidelines. Uve-
itis was registered as present and active, when the oph-
thalmologist prescribed treatment for inflammation inthe uvea. Uveitis was classified according to the recom-
mendations by the Standardization of Uveitis Nomen-
clature (SUN) working group [22]. Uveitis was
classified as “acute”; symptomatic with acute onset,
sometimes recurrent course but of limited duration, or
“chronic”; insidious onset, mainly asymptomatic with
chronic recurrent or persistent course. Collected data also
included locally analyzed HLA-B27, antinuclear antibodies
(ANA) and rheumatoid factor (RF), and a positive result
of the latter two had to be confirmed, at least 3 months
apart. Each physician interpreted the results of ANA and
RF analysis as positive or negative according to the refer-
ence values of their local laboratory; the cut-off value
for a positive test was ≥ 1/80 in Tromsø, Trondheim
and parts of Sweden, ≥ 1/320 in Finland, and ≥ 1/160 in
Copenhagen, Århus and some parts of Sweden. ANA was
measured using immunofluorescence on HEp-2 cells.
Serum was taken at a median of 4 (1st quartile of 2, 3rd
quartile of 7) months after the disease was diagnosed, fro-
zen and stored at −70 °C in aliquots to avoid repeated
freeze-thaw cycles. AHA were detected with Varelisa His-
tone Antibodies Enzyme Induced Assay (EIA) kit for anti-
histone IgM/IgG antibodies using a combined IgM/IgG
conjugate (Phadia Diagnostics, Freiburg, Germany) at UIT
The Arctic University of Norway, Tromsø, Norway. Tests
were run according to the manufacturer’s instructions
[23]. According to the kit instructions a level ≥ 30 U/ml is
considered positive, 15–29 U/ml borderline, and < 15 U/
ml negative, based on a test population of 432 healthy
adults, normative values are not given for children. In the
present study, we investigated ≥ 15 U/ml as a positive
threshold based on our previous study reporting a mean
concentration of 4.3 U/ml in 58 healthy children utilizing
the same Varelisa Histone EIA-kit [11]. The presence of
AHA in a Norwegian JIA cohort, also including the Nor-
wegian subsets of this Nordic JIA cohort, has previously
been reported and was therefore not included here [11].
No sera were available from the Finnish participants, and
subsequently analyses of the AHA were performed only in
the Swedish and Danish sera.
Approval from medical research ethical committees
and data protection authorities was granted according to
the regulations of each participating country, in Norway
from Regional Committee for Medical and Health
Research Ethics NORD, number 53/96. Oral informed
assent was obtained from all children. Written in-
formed consent was obtained from parents of children
aged < 16 years and from the children if aged ≥ 16 years.
Statistical analyses
The study report followed the STROBE guidelines [24].
Statistical analyses were performed using the STATA
version 14 software (STATA Corp., College Station, TX,
USA). Descriptive statistics were used to summarize
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tivity measures. The chi-square test was used as appro-
priate for comparison of categorical variables. The
Student’s t-test was used to compare means in continu-
ous outcomes between groups, and Mann-Whitney rank
sum test for comparison of medians for skewed data. A
logistic regression analysis of baseline characteristics was
performed to calculate odds ratio for developing uveitis.
The p-value <0.05 was considered significant.
Results
Regular ophthalmologic follow-up for more than 7
years was available in 435 (87.0%) of the 500 children
included in the prospective multi-centre Nordic JIA-
cohort; 60 children were lost to follow-up, and in 5
children long-term ophthalmological data were missing.
Baseline clinical characteristics of the group with or
without long-term follow-up were mostly similar and
have previously been published [21].
Incidence
Uveitis developed in 89 (20.5%) of the 435 children.
Clinical characteristics at baseline according to the pres-
ence of acute and chronic uveitis is shown in Table 1.
Among the 9 children with acute uveitis, 8 had
enthesitis-related arthritis (ERA), and 7 were HLA-B27
positive. Chronic insidious uveitis developed in 80
(18.4%) children. The cumulative incidence of uveitisTable 1 Clinical characteristics at the first study visit in 435 children
to the presence of acute or chronic uveitis during > 7 years of follow
All children No uve
N N
Female gender 435 286 (65.8) 346
Age at onset, median (1st, 3rd q) 435 5.5 (2.4, 9.5) 346
Oligoarticular onseta 435 224 (51.5) 346
ANA positive 427 116 (27.2) 340
AHA >15 U/ml 134 23 (17.2) 112
RF positive 424 10 (2.4) 336
HLA-B27 positive 413 87 (21.1) 325
ESR, median (1st, 3rd q) 354 14 (8, 28) 276
CRP, median (1st, 3rd q) 350 0 (0, 10) 276
JADAS27, median (1st, 3rd q) 194 5.1 (2.0, 11.0) 157
CHAQ, median (1st, 3rd q)) 273 0.3 (0.0, 1.0) 222
DMARD use 2nd visitb 350 125 (35.6) 316
Data are presented as numbers (%), unless otherwise noted
ANA antinuclear antibodies measured by immunofluorescence on Hep-2 cells, and R
with one or more tests taken, AHA > 15 U/ml antihistone antibodies IgM/IgG >15 U/
arthritis in years, ESR erythrocyte sedimentation rate, CRP C-reactive protein JADAS2
health assessment questionnaire
aOligoarticular JIA 6 months after disease onset, according to the International Leag
bPercentage of DMARD = Disease modifying anti-rheumatic drugs including biologi
children without uveitis at the time of the 2nd study visit, differentiating into no uvaccording to the International League of Associations
for Rheumatology (ILAR) categories is shown in Table 2.
There were no uveitis in the systemic nor in the polyar-
ticular RF positive categories, and highest incidence was
noted in the juvenile psoriatic arthritis (35.7%) and
enthesitis-related arthritis (25.0%) categories. The inci-
dence of uveitis was significantly higher in Finland than
in the other Nordic countries (Table 3). Finland also had
the highest proportion of children with young age at on-
set of JIA, but neither gender, oligoarticular onset nor
the prevalence of HLA-B27, ANA, or AHA showed any
corresponding difference between countries.
Time from onset of arthritis to onset of uveitis is
shown in Fig. 1, including 5 children in which uveitis
was diagnosed before the arthritis, one of these had
acute uveitis. Uveitis developed within the first year after
onset of arthritis in 48 (53.9%), within 4 years in 73
(82.0%) of the children, and 4 children (4.5%) had onset
of uveitis more than 8 years after onset of arthritis, 2 of
these had chronic asymptomatic uveitis. The number of
children developing uveitis within the first year after on-
set of arthritis is 6 times the number developing uveitis
during the second year, and 16 times the number during
the fifth year. All together uveitis developed with an
interval of median 0.8 (range − 4.7 to 9.4) years after on-
set of arthritis, while chronic uveitis developed with a
median interval of 0.7 (range − 3.0 to 8.6) years after on-
set of arthritis.in the Nordic juvenile idiopathic arthritis (JIA) cohort according
-up
itis Acute uveitis Chronic uveitis
N N
227 (65.6) 9 4 (44.4) 80 55 (68.8)
6.2 (2.8, 10) 9 10.8 (9.3, 12.9) 80 3.2 (1.8, 5.9)
180 (52.0) 9 1 (11.1) 80 43 (53.8)
79 (23.2) 9 0 (0) 78 37 (47.4)
14 (12.5) 3 1 (33.3) 19 8 (42.1)
9 (2.7) 9 1 (11.1) 79 0 (0.0)
62 (19.1) 9 7 (77.8) 79 18 (22.8)
14 (8, 26) 8 23 (10, 41) 70 16 (9, 36)
0 (0, 10) 9 0 (0, 16) 65 0 (0, 14)
5.0 (2.0, 9.8) 7 10.4 (5.6, 14.9) 30 3.8 (1.6, 12.5)
0.4 (0.0, 1.0) 8 0.4 (0.1, 1.2) 43 0.3 (0.0, 1.0)
111 (35.1) 7 3 (37.5) 27 11 (42.3)
F rheumatoid factor; two positive tests taken > 3 months apart in participants
ml, HLA-B27 human leucocyte antigen B27, Age at onset age at onset of
7 Juvenile arthritis disease activity score based on 27 joint count, CHAQ Child
ue of Associations for Rheumatology (ILAR) classification criteria. [25]
cal agents used within the 2nd visit (median 13 months (IQR 12–14)) in 350
eitis, acute, or chronic uveitis during further follow-up
Table 2 Presence of acute or chronic uveitis in the different JIA categories according to the International League of Associations for
Rheumatology (ILAR) classification criteria at the final study visit in 435 children in the Nordic juvenile idiopathic arthritis (JIA) cohort
JIA category All children
n = 435 (% of all)
No uveitis
n = 346 (%)
Acute uveitis
n = 9 (%)
Chronic uveitis
n = 80 (%)
Cumulative total uveitis
incidence (95% CI)a
Systemic 18 (4.1) 18 (100.0) 0 (0) 0 (0) 0 (0, 18.5)
Oligoarticular persistent 131 (30.1) 106 (80.9) 0 (0) 25 (19.1) 19.1 (12.7, 26.9)
Oligoarticular extended 78 (17.9) 62 (79.5) 0 (0) 16 (20.5) 20.5 (12.2, 31.2)
Polyarticular RF negative 80 (18.4) 62 (77.5) 0 (0) 18 (22.5) 22.5 (13.9, 33.2)
Polyarticular RF positive 3 (0.7) 3 (100.0) 0 (0.0) 0 (0.0) 0 (0, 70.8)
Juvenile psoriatic arthritis 14 (3.2) 9 (64.3) 0 (0.0) 5 (35.7) 35.7 (12.8, 64.9)
Enthesitis-related arthritis 48 (11.0) 36 (75.0) 8 (16.7) 4 (8.3) 25.0 (13.6, 39.6)
Undifferentiated arthritis 63 (14.5) 50 (79.4) 1 (1.6) 12 (19.0) 20.6 (11.5, 32.7)
aCI, confidence interval
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Young age at onset of JIA and ANA were significant
predictors of uveitis (Tables 4 and 5). AHA ≥ 15 U/ml was
found in 23 (17.2%) and AHA ≥ 30 U/ml in 10 (7.5%) of
the 134 participants with AHA analyses. AHA ≥ 30 U/ml
was found in 3 of the 5 females with uveitis and AHA ana-
lyses. The presence of AHA ≥ 15 U/ml was significantly
higher in children with uveitis than in children without
(OR 4.8 (1.8 to 13.4)) (Table 4). Serum concentration of
AHA IgM/IgG antibodies was significantly higher in the
group with uveitis (mean 19.2 U/ml) than in children
without uveitis (mean 10.2 U/ml) in the Swedish and
Danish cohort with available sera for antihistone analyses
(p = 0.002; chi-square, data not shown).
Neither gender, oligoarticular onset nor other ILAR cat-
egories predicted uveitis. Presence of HLA-B27 was bor-
derline significant as a predictor of uveitis, primarily
because there was a high presence of HLA-B27 among
children with acute uveitis (Tables 1 and 4). There was no
significantly reduced risk of developing uveitis in children
that had started disease-modyfing antirheumatic drug
(DMARD) treatment, including biologics, neither at the
first (data not shown) nor at the second study visit (Tables
1 and 4), taking into account the start date of DMARDsTable 3 Presence of uveitis, antinuclear antibodies, antihistone antib
children in the Nordic juvenile idiopathic arthritis (JIA) cohort
Denmark n = 91 Norway
No uveitis 73 (80.2) 86 (81.9
Acute uveitis 3 (3.3) 4 (3.8)
Chronic uveitis 15 (16.5) 15 (14.3
Female gender 62 (68.1) 67 (70.5
Oligoarticular onset 45 (49.5) 51 (48.6
Age at onset 4.8 (2.2, 9.3) 5.9 (2.8,
ANA positive 28 (30.8) 32 (32.0
HLA-B27 positive 14 (15.6) 29 (27.6
Data are numbers (percent) except median (1st and 3rd quartile) for Age at onset; age
on Hep-2 cells, two positive tests taken more than 3 months apart in participants withand the date of diagnosis of uveitis. At the final study visit
the percentage of children ever using DMARDs was
higher in the uveitis group (78.7%) compared to the group
without uveitis (53.2%) (data not shown), but the number
of children receiving DMARDs to treat primarily their
uveitis is not known. These analyses on DMARDs were
also performed for methotrexate, showing the same result.
There were no significant difference in incidence of uveitis
in children that had used etanercept (18.5%) during the
disease course versus those that never used etanercept
(20.7%), p = 0.706. Also the incidence of uveitis was similar
in children that had used sulfasalazine (16.1%) versus
those that never used sulfasalazine (21.2%), p = 0.361. Dur-
ing the disease course, 14.3% of the cohort used sulfasa-
lazine, while 12.4% used etanercept. The main predictors
of uveitis in Table 4 were stratified for gender (Table 5).
This analysis showed that girls with uveitis had a lower
median age at onset of arthritis of 3.4 versus 6.8 in girls
without uveitis (p < 0.001). The difference in age at onset
was highly significant in girls, but not in boys (p = 0.390)
(Tables 4 and 5). ANA was a significant predictor, both in
girls and in boys (Table 4). Analysis stratified for gender
showed that median median AHA was significantly higher
in girls (p = 0.003), but not in boys (p = 0.794) (Table 5).ody levels and HLA-B27 according to country of origin in 435
n = 105 Sweden n = 101 Finland n = 138
) 87 (86.1) 100 (72.5)
1 (1.1) 1 (0.7)
) 13 (12.9) 37 (26.8)
) 67 (66.3) 83 (60.1)
) 55 (54.5) 73 (52.9)
9.9) 6.9 (3.2, 11.3) 5.1 (2.3, 8.7)
) 23 (22.8) 33 (24.4)
) 20 (21.5) 24 (19.2)
at onset of arthritis, ANA antinuclear antibodies measured by immunofluorescence
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Fig. 1 Onset of uveitis in years after onset of arthritis in 435 children
in the Nordic JIA cohort, including 5 children developing uveitis before
onset of arthritis (time 0)
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In this Nordic multicenter JIA study, we found a high
cumulative incidence of uveitis, and a geographic differ-
ence with a higher incidence in Finland compared to
Norway, Sweden and Denmark. Young age at onset of
arthritis, ANA and AHA were significant predictors of
uveitis, but stratified for gender both young age at onset
and AHA were significant predictors only in girls. Mean
serum levels of AHA were higher in the uveitis group
than in the children with no uveitis.
The prospective, longitudinal design and population-
based context are the strengths of this multi-center
study. The proportion of children lost to follow-up wasTable 4 Baseline clinical and demographic predictors of uveitis
in 435 participants in the Nordic juvenile idiopathic arthritis (JIA)
cohort
No uveitis Uveitis OR (95% CI)
N n (%) N n (%)
Female gender 346 227 (65.6) 89 59 (66.3) 1.0 (0.6, 1.6)
Oligoarticular onset 346 168 (48.6) 89 41 (46.1) 0.9 (0.6, 1.4)
Age at onset (< 7 years) 346 189 (54.6) 89 64 (71.9) 2.1 (1.3, 3.5)
ANA positive 340 79 (23.2) 87 37 (42.5) 2.4 (1.5, 4.0)
AHA > 15 U 112 14 (12.5) 22 9 (40.9) 4.8 (1.8, 13.4)
HLA-B27 positive 325 62 (19.1) 87 25 (28.7) 1.7 (1.0, 2.9)
ESR > 20 mm/H 276 95 (34.4) 78 34 (43.6) 1.5 (0.9, 2.5)
CRP > 10 mg/L 276 77 (27.9) 74 27 (36.5) 1.5 (0.9, 2.6)
DMARD use ≤ 2nd visita 316 111 (35.1) 34 14 (41.2) 1.3 (0.6, 2.7)
aIn 350 children with no uveitis at the time of 2nd study visit, percentage of
DMARD used within 2nd visit (median 13 (1st q 12, 3rd q 14) months) in children
with no uveitis versus children with uveitis during further follow-up.
Odds ratio (OR) of developing uveitis calculated with logistic regression.
Oligoarticular onset, oligoarticular category 6 months after onset of disease,
according to the International League of Associations for Rheumatology
(ILAR) classification criteria (5); ANA antinuclear antibodies measured by
immunofluorescence on Hep-2 cells two positive tests taken > 3 months
apart in participants with one or more tests takensmall compared to other longitudinal studies [26–29]. A
weakness is the few patients in each JIA category that
made analyses of uveitis and its predictors in some of
the categories less reliable. Another weakness is that in-
formation on uveitis such as differentiation between
acute and chronic uveitis were registered from available
ophthalmologic records by the pediatric rheumatologists
and not by the ophthalmologists themselves.
The high rate of uveitis in our population is in line with
previous findings in the Nordic countries [6, 11, 30, 31]. A
prevalence of 8–15% was reported from Sweden [30, 32],
14–18% in northern Norway [11, 31], 9–19% in Denmark
[33, 34], while higher rates were previously reported from
Finland (24%) [6, 35]. Even though the background rate of
HLA-B27 is reported to be higher in northern areas such
as Finland and northern Norway [36, 37], we did not find
this in our cohort from the Helsinki area in the southern
part of Finland. There were also no differences in the
presence of ANA between countries. The higher incidence
of uveitis during the first 8 years of disease in Finland
compared to the other Nordic countries in the present
study may be explained by the trend of younger age at on-
set of arthritis in Finland and/or genetic differences. This
finding is in line with the striking worldwide ethnic and
genetic differences in uveitis incidence, differences beyond
what can be expected by variations in patient accrual
and study design. In two large studies from North Amer-
ica of multiethnic populations both Saurenmann et al. and
Angeles-Han et al. found that uveitis was more common
among Caucasians than among children of black Ameri-
can, Arab and Indian origin [12, 13]. Our cohort was of
mostly Caucasian origin.
In line with other studies we found that the risk of
developing uveitis during the first year was more than 6
times the risk during the second year, and almost 16-
fold the risk during the fifth year after onset of arthritis.
This underlines the need for immediate eye examination
in children with onset of non-septic or non-specific arth-
ritis even before the diagnosis of JIA is confirmed, and
frequent early follow-up when a diagnosis of JIA has
been established. Even though a clear majority of 82%
developed uveitis within the first 4 years, our data show
that uveitis may develop late in the JIA disease course.
An important finding was that 4 cases of uveitis devel-
oped more than 8 years after onset of arthritis. Of these
cases 2 were asymptomatic uveitis, which may not have
been diagnosed without long-term screening. Zak et al.
found in their 26-years follow-up of a Danish JIA cohort
that both new onset of uveitis and complications may
develop late [26]. Based on these data long-term ophthal-
mologic follow-up into adulthood must be considered.
Robust predictors of uveitis will help selecting high-
risk children for frequent eye examinations to ensure
early diagnosis and treatment. In acute uveitis with
Table 5 Age at onset of arthritis, antihistone antibody levels and presence of antinuclear antibodies according to gender and
presence of uveitis in 435 participants in the Nordic juvenile idiopathic arthritis (JIA) cohort
No uveitis Uveitis p
n Age at onset of arthritis n Age at onset of arthritis
Female 227 6.8 (2.5, 10.4) 59 3.4 (1.7, 7.5) < 0.001
Male 121 5.9 (3.2, 9.2) 27 3.9 (2.3, 7.9) 0.390
n Presence of ANA n Presence of ANAa
Female 222 65 (29.3) 59 27 (45.8) 0.016
Male 118 14 (11.9) 28 10 (35.7) 0.002
n AHA IgM/IgG U/ml n AHA IgM/IgG U/ml
Female 72 6.9 (5.2, 11.4) 16 14.2 (7.2, 27.9) 0.003
Male 40 7.1 (4.7, 11.0) 6 8.2 (4.5, 11.4) 0.794
ANA antinuclear antibodies measured by immunofluorescence on Hep-2 cells, two positive tests taken >3 months apart in participants with one or more tests
taken. AHA antihistone IgM/IgG antibodies U/ml, analyzed only in the Swedish and Danish cohort
anumbers (percent), analysed by Chi-square test, otherwise median (1st, 3rd quartile), analyzed with Mann-Whitney rank sum test
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important, but the differentiation between acute and
chronic uveitis is not always clear, and young children
may have difficulties expressing complaints of a painful
acute uveitis. In line with most publications we have
therefore chosen to analyze predictors of all forms of
JIA-associated uveitis and compared with children with-
out uveitis [3, 12, 13]. The most consistently reported
predictor of uveitis is young age at onset of arthritis. In
line with Saurenmann et al. our data confirms that
young age at arthritis onset implies high risk of uveitis
in girls, but not in boys [38]. The predictors of uveitis
are different in girls and boys, even though the rate of
uveitis did not differ. This may reflect that different cat-
egories of JIA have different types of uveitis with differ-
ent predicting factors. ANA is another well-documented
predictor of uveitis, but this applies only to the immuno-
fluorescence method, and not to the more automatized
high-throughput method of ANA ELISA. We were not
able to find the gender-specific differences of ANA that
Saurenmann et al. found in their Canadian study [38],
but there were few ANA positive boys with uveitis in
our study.
We found increased risk of uveitis in children with
high levels of antihistone antibodies. Previous findings in
the Norwegian JIA cohort were now confirmed in 134
Swedish and Danish children, in whom significantly
higher baseline serum levels of histone antibodies were
found among those who developed uveitis compared to
those who did not develop uveitis [11]. In these studies,
the histone antibody levels were either borderline posi-
tive (≥ 15 U/ml) or positive (≥ 30 U/ml) according to the
commercial test, however, the test and the cut-offs are
established to detect drug-induced or other types of sys-
temic lupus erythematosus in adults [23]. While the
mean serum concentration of combined antihistone IgMand IgG antibodies was 19.2 U/ml in children with uve-
itis, and 10.2 U/ml in children without uveitis, a mean
concentration of 4.3 U/ml was found in healthy children
in our previous report utilizing the identical type of
AHA EIA kit [11]. The reproducibility of this finding
should be tested in other cohorts. Epigenetic modifica-
tions of histone such as acetylation and methylation are
suggested to be involved in the pathological processes of
autoimmunity [18], and may also play a role in the eti-
ology of uveitis [39]. However, no specific intra-ocular
antigen has been identified as the target of neither ANA
nor AHA, and therefore their potential role in patho-
physiology and etiology remains unclear. The presence
of ANA immunofluorescence and AHA had similar test
properties as predictors of uveitis, but with less predict-
ive ability as the simple measure of young age at onset
of arthritis. There is an ongoing discussion on classifica-
tion in JIA. ANA positive young children are a quite
homogeneous group regarding disease characteristics in-
cluding high risk of uveitis the first 2 years after onset
[40, 41]. It is interesting that the higher risk of uveitis in
girls with young age at onset, was shown also for girls
with higher levels of histone antibodies in our study.
Whether young girls with uveitis, presence of ANA and
AHA constitutes a biological subset among children
with JIA remains to be shown.
We analyzed the onset of uveitis in relation to early
DMARD treatment, and found that early DMARD or
methotrexate treatment did not seem to prevent later
development of uveitis. The inclusion period in our
cohort was too short for analyses of prevalence in differ-
ent time periods, the onset of disease was in the very be-
ginning of the era of biologic agents, and our data are
therefore of limited value in clarifying any uveitis-
protective potential of specific drugs or modern DMARD
treatment in general. Tappeiner et al. have compared
Nordal et al. Pediatric Rheumatology  (2017) 15:66 Page 7 of 8prevalence of uveitis in German children with JIA in two
time periods up to 2013, and found a lower prevalence in
the latest period when DMARDs including biologic agents
were more commonly used [42]. Whether DMARDs can
prevent or only postpone development of uveitis in JIA is
not known.
Conclusion
We found a high prevalence of uveitis in this Nordic JIA
population-based cohort. Significant predictors of uveitis
were young age at onset of arthritis and presence of AHA
in girls, and presence of ANA in both genders. Further
long-term follow-up are needed to focus on prevalence of
late-onset uveitis, presence of complications, and impact on
quality of life in young adults with JIA-associated uveitis.
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